

Application Serial No.: 10/801,608
Inventor(s): Allegrini et al.
Attorney Docket No.: 100506-00023

III. REMARKS AND CONCLUSION


The applicants thank the examiner for the telephone conversation of July 28, 2005. As instructed by the examiner, and merely to expedite issuance of the previously allowed application, the applicants have amended the specification to capitalize the drug names. Similarly, the applicants have amended the claims to add the chemical formulae of the claimed drugs (claims 8 and 10), to better correspond to U.S. patent practice (claim 4), to correct minor typographical errors (claims 3 and 5), and to convert a dependent claim to independent form (claim 7).

Support for the amendments to the specification and claims may be found throughout the specification and claims as originally filed (see, for example, page 3, line 28 to page 5, line 7). Therefore, the applicants believe that no new matter is added. The applicants respectfully request entry of this Amendment under 37 C.F.R. §1.312, in that the amendments are made prior to payment of the issue fee and do not require a new search or examination of the allowed claims.

The applicants believe that no fee is due for the consideration of this Amendment. If a fee is required, it may be charged to Deposit Account No. 01-2300, referencing Attorney Docket No. 100506-00023.

Respectfully submitted,

ARENT FOX PLLC


Gautam Brakash, Ph.D.
Registration No.: 53,481
Direct Telephone No.: 202-857-6057

Customer No.: 004372

1050 Connecticut Avenue, N.W.
Washington, D.C. 20036-5339

Telephone No.: 202-857-6000
Facsimile No.: 202-857-6395

/GP

BEST AVAILABLE COPY

RPP/126037.1

10